Versartis Trial in Children to Assess Long-Acting Growth Hormone

Model scores of the 29,894 trials active now.

Model score 15% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (95 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-07-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: stagelymphomagrowthpediatricto determine
  Phrases that lowered it: hormonepharmacodynamicstolerability pharmacokineticsat screeningsignificant
• Phase: 1/2 (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Disease area, cancer: No (lowers risk) · Disease area
• Design: single group (raises risk) · Design
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Maximum age: 11 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Disease area, musculoskeletal: Yes (raises risk) · Disease area
• Blinding: none (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Minimum age: 3 (lowers risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Collaborators: 0 (raises risk) · Design
• Keywords listed: 10 (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Versartis International Trial in Adults With Long-Acting Growth Hormone NCT02526420 · started 2015 · scored riskier than 56% of active trials completed
• Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317) NCT02413138 · started 2015 · scored riskier than 19% of active trials terminated
• VRS-317 in Adult Subjects With Growth Hormone Deficiency NCT01359488 · started 2011 · scored riskier than 39% of active trials completed
• Long-Acting Growth Hormone in Children Compared to Daily rhGH NCT02339090 · started 2015 · scored riskier than 24% of active trials completed
• A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children NCT02092077 · started 2014 · scored riskier than 26% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.